NCT07193901View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of PRT-042 Nasal Spray for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

PHASE2RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Major Depressive Disorder (MDD
Interventions
DRUG

Low Dose PRT042 nasal spray

two times a week, for 4 weeks

DRUG

median Dose PRT042 nasal spray

two times a week, for 4 weeks

DRUG

high dose PRT042 nasal spray

two times a week, for 4 weeks

DRUG

placebo

two times a week, for 4 weeks

Trial Locations (8)

Unknown

RECRUITING

BEIjing AnDing hospital capital medical university, Beijing

RECRUITING

Beijing AnDing hospital capital medical university, Beijing

RECRUITING

Beijing Huilongguan Hospital, Beijing

RECRUITING

The Fourth People's Hospital of Chengdu, Chengdu

RECRUITING

Hangzhou Seventh People's Hospital, Hangzhou

RECRUITING

The fourth affiliated hospital of Anhui medical university, Hefei

RECRUITING

The affiliated Kangning Hospital of Ningbo University, Ningbo

RECRUITING

Suzhou Guangji Hospital, Suzhou

All Listed Sponsors
lead

Sichuan Purity Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT07193901 - A Study to Assess the Efficacy and Safety of PRT-042 Nasal Spray for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide | Biotech Hunter | Biotech Hunter